Showing results (171-180 of 188) with videos related to
Sort By:
Pageof 19
Leukemia & Lymphoma|July 1, 1994
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignanciesL C Platanias, M J Ratain, S O'Brien, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B studyR C Lilenbaum, M J Ratain, A A Miller, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neckB Brockstein, D J Haraf, K Stenson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264A P Venook, M J Egorin, G L Rosner, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 1998
A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancerE E Vokes, R H Ansari, G A Masters, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2003
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863A P Venook, C Enders Klein, G Fleming, et al.Leukemia & Lymphoma|July 28, 2016
Survival Experience of 195 Patients with Hairy Cell Leukemia Treated in a Multi-Institutional Study with Interferon-Alfa 2BH M Golomb, A Fefer, D W Golde, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancerC M Rudin, J Holmlund, G F Fleming, et al.Clinical and Translational Science|January 22, 2016
Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics ModelingC H Li, R R Bies, Y Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancerN J Vogelzang, S Mani, R L Schilsky, et al.Pageof 19